戴维医疗
(300314)
| 流通市值：21.03亿 | | | 总市值：42.13亿 |
| 流通股本：1.44亿 | | | 总股本：2.88亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 421,295,096.77 | 251,904,726.04 | 112,797,919.57 | 584,030,132.77 |
| 营业收入 | 421,295,096.77 | 251,904,726.04 | 112,797,919.57 | 584,030,132.77 |
| 二、营业总成本 | 373,921,672.07 | 234,310,985.64 | 106,008,569.07 | 506,371,105.43 |
| 营业成本 | 208,028,498.32 | 125,172,039.94 | 56,493,086.26 | 270,868,395.16 |
| 税金及附加 | 4,361,573.48 | 3,475,795.53 | 1,115,729.45 | 7,108,903.38 |
| 销售费用 | 59,644,437.6 | 37,276,912.25 | 18,403,805.43 | 100,993,412.96 |
| 管理费用 | 57,517,710.08 | 35,871,029.71 | 14,965,923.94 | 73,820,201.42 |
| 研发费用 | 34,116,249.7 | 22,721,922.56 | 10,534,738.58 | 59,304,913.48 |
| 财务费用 | 10,253,202.89 | 9,793,285.65 | 4,495,285.41 | -5,724,720.97 |
| 其中:利息费用 | 175,795.3 | 126,099.87 | 65,554.34 | 428,890.08 |
| 其中:利息收入 | 10,175,605.28 | 6,532,827.88 | 3,358,935.44 | 12,309,333.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 34,176,957.52 | 4,179,684.59 | 1,426,183.95 | 1,777,206.29 |
| 加:投资收益 | 1,061,881.45 | 1,761,581.5 | 1,230,564.44 | 13,529,780.77 |
| 资产处置收益 | 19,008.79 | 19,008.79 | - | -389,071.48 |
| 资产减值损失(新) | -1,462,184.68 | -1,462,184.68 | - | -2,140,826.65 |
| 信用减值损失(新) | 504,778.38 | 272,143.97 | -298,756.63 | -1,323,457.98 |
| 其他收益 | 5,130,217.77 | 4,326,822.8 | 2,435,517.67 | 9,535,432.81 |
| 四、营业利润 | 86,804,083.93 | 26,690,797.37 | 11,582,859.93 | 98,648,091.1 |
| 加:营业外收入 | 302,464.72 | 58,063.12 | 18,102.78 | 345,739.72 |
| 减:营业外支出 | 335,029.37 | 294,101.56 | 275,165.45 | 336,349.97 |
| 五、利润总额 | 86,771,519.28 | 26,454,758.93 | 11,325,797.26 | 98,657,480.85 |
| 减:所得税费用 | 9,075,356.92 | 2,366,801.55 | 1,439,978.75 | 11,604,161.16 |
| 六、净利润 | 77,696,162.36 | 24,087,957.38 | 9,885,818.51 | 87,053,319.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 77,696,162.36 | 24,087,957.38 | 9,885,818.51 | 87,053,319.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 77,696,162.36 | 24,087,957.38 | 9,885,818.51 | 87,053,319.69 |
| 扣除非经常损益后的净利润 | 44,309,597.15 | 16,291,601.48 | 6,173,470.82 | 67,024,300.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.08 | 0.03 | 0.3 |
| (二)稀释每股收益 | 0.27 | 0.08 | 0.03 | 0.3 |
| 八、其他综合收益 | -1,616,368.67 | -1,920,793.38 | -407,408.33 | 2,662,473.46 |
| 归属于母公司股东的其他综合收益 | -1,616,368.67 | -1,920,793.38 | -407,408.33 | 2,662,473.46 |
| 九、综合收益总额 | 76,079,793.69 | 22,167,164 | 9,478,410.18 | 89,715,793.15 |
| 归属于母公司股东的综合收益总额 | 76,079,793.69 | 22,167,164 | 9,478,410.18 | 89,715,793.15 |
| 公告日期 | 2026-10-23 | 2026-08-21 | 2026-04-23 | 2026-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |